The study that suggests that the combination of gemcitabine, rituximab, oxaliplatin, and pegfilgrastim iseffective as a salvage regimen for relapsed non-Hodgkin’s lymphoma (NHL) and is less toxic was presented at the 2008 meeting of the American Society of Clinical Oncology in Chicago May 30-June 2.It included 37 patients with relapsed aggressive NHL treated with gemcitabine, rituximab, oxaliplatin (GROC) and pegfilgrastim given every 14 days. The results were compared with other salvage regimens. Anotheh study od forty-six patients with relapsed or refractory B-cell lymphoma who received up to eight cycles of R-GemOx (rituximab 375 mg/m2 on day 1, gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 on day 2). showed that after four cycles of R-GemOx, the overall response rate was 83% [50% complete response (CR)/unconfirmed CR (CRu)]. High CR/CRu rates were observed in all histological subtypes. Among responders, the probability of being disease free for 2 years was 62% and treatment was generally well tolerated. There were no patients who failed transplant in these studies.
Reliable evidence shows that experts consider farther studies necessary and this defines this regimen as being experimental as per most plan languages.
Cabanillas F, Liboy I, Rodriguez-Monge E, et al. GROC (gemcitabine, rituximab, oxaliplatin combination) plus pegfilgrastim is less toxic and as active as DHAP and ESHAP for relapsed aggressive non-Hodgkin’s lymphoma (NHL). Journal of Clinical Oncology. 2008;26:abstract 8530.
T El Gnaoui , J Dupuis , K Belhadj , J-P Jais , A Rahmouni , C Copie-Bergman , I Gaillard , M Diviné , I Tabah-Fisch , F Reyes , and C Haioun
Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy
Annals of Oncology Advance Access published on May 11, 2007, DOI 10.1093/annonc/mdm133.